
    
      The (repeated) use of LAT to â‰¤ 3 OP lesions with continuation of first-line osimertinib, is
      endorsed by international guidelines (NCCN, ESMO).

      In this phase IIb prospective non-randomized observational trial, we want to document the
      benefit of LAT in this patient cohort.
    
  